Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Amex CVM ex HIV -- Ignore unavailable to you. Want to Upgrade?

To: BostonView who wrote (1)	2/11/2000 4:30:00 PM
From: ccryder	Read Replies (1) \| Respond to of 25

The Biotech sector has gotten a shot in the arm from the president's promise to spend more tax money on research. It seems that some analysts have been promoting the biotech sector as cheap compared to the electonic/computer/network, etc. tech stocks. Of more interest to me is CelSci's letter to stockholders 'warning' of progress towards a Multikine phase 3 trial because of "compelling results" from the phase 2 trials. Never before have I heard this company produce any bullish warnings of this kind in advance of peer reviewed articles in journals or conferences. They have told of plans to open a laboratory to support the Phase 3 trials and then there is the stock symbol change. In addition, the recent split of the CelSci forming a company to concentrate on the L.E.A.P.S. technology and subsequent announcement of several collaborative efforts to develop the technology for treating many immune system disorders and diseases is a real positive development. Just think of cures for arthritis, hepatitis, not to mention disabling a tiny portion of the immune system so transplants are not rejected.